Strong Revenue Growth#
AMS, a UK-based company specializing in tissue-healing devices, announced a remarkable 29% revenue growth for 2025. This increase is attributed to both organic expansion—meaning growth from existing operations—and strategic acquisitions that have broadened their market reach.
Financial Performance#
The company reported an adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increase of 24%, indicating improved operational profitability. Adjusted diluted earnings per share (EPS), which reflects the portion of a company's profit allocated to each share of common stock, rose by 12% year-over-year, reaching £0.12. For the full year, AMS also reported a pretax profit of £33.90 million, compared to £17.80 million in the previous year.
Dividend Increase#
In light of its positive financial outlook, AMS's board has proposed a 10% increase in the full-year dividend. This move reflects the company's confidence in sustaining its growth trajectory and rewarding shareholders.
Future Expectations#
Looking ahead to 2026, AMS projects revenue of £245.3 million and an adjusted EBITDA of £55.2 million. The company expects continued robust performance in its Surgical division, particularly in adhesives, biosurgical devices, and sutures, with significant growth anticipated in the US and Asia-Pacific markets. The Woundcare segment has also returned to growth following a restructuring, aided by new supply agreements and a focus on higher-margin products. AMS is optimistic about securing multiple product approvals in the coming years, particularly in adhesives, sutures, and collagen technologies.